



JOIN US FOR AN

EDUCATIONAL SESSION ON HEMLIBRA

For people with hemophilia A with or without factor VIII inhibitors

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- **Thrombotic microangiopathy (TMA)**, a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events)**, which may form in blood vessels in your arm, leg, lung, or head

Please see Important Safety Information, including **Serious Side Effects**, as well as the accompanying HEMLIBRA full Prescribing Information and Medication Guide.



SESSION

INFORMATION

It's A Feeling. If You Know You Know



Thursday, August 10, 2023

6:30 PM CT

Meal will be provided



Paisano's Ristorante

4043 SW 10th Ave

Topeka, KS, 66604



HOSTED BY:

Bobbi Sellers, MBA, MSN, RN

Genentech Hemophilia Account Community Manager (ACM)



HEAR FROM:

Bobbi Sellers, MBA, MSN, RN

Tamar M, HEMLIBRA AMBASSADOR

REGISTER TODAY FOR THIS EDUCATIONAL PROGRAM

RSVP to Angela Brown (816)479-5900 or <https://midwesthemophilia.org> by Friday, 8/04/2023

This program, sponsored by Genentech, will not provide medical advice. Speak with your healthcare provider if you have questions about your medical condition or treatment. ACMs are Genentech employees. ACMs do not provide medical advice.

What is the most important information I should know about HEMLIBRA? (continued)

Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
- You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including **Serious Side Effects**, as well as the accompanying HEMLIBRA full [Prescribing Information](#) and [Medication Guide](#).

Genentech
A Member of the Roche Group

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
© 2023 Genentech USA, Inc. All rights reserved. For U.S. residents only. M-US-00003251(v5.0) 03/23


HEMLIBRA®
emicizumab-kxwh | 150 mg/mL
injection for subcutaneous use